Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

FDA Lays Out Which Postapproval Manufacturing Changes for Biologics Are ‘Minimal’

Which manufacturing changes have the least potential to adversely affect product quality? That’s the question the FDA has attempted ...

Forward this item to a colleague:

(Separate multiple addresses by commas)